|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1996 | Volume 125 Issue 11 | Pages 883-890
Background: Patients with adult-onset growth hormone deficiency have reduced bone density and increased fat mass. Growth hormone at high doses may decrease body fat in these patients, but the effects of growth hormone at more physiologic doses on bone density and body composition have not been convincingly shown.
Objective: To determine whether long-term growth hormone therapy at a dose adjusted to maintain normal insulin-like growth factor 1 (IGF-1) levels has clinical effects in patients with adult-onset growth hormone deficiency.
Design: Randomized, placebo-controlled study.
Setting: Tertiary referral center.
Patients: 32 men with adult-onset growth hormone deficiency.
Intervention: Growth hormone (initial daily dose, 10 µg/kg of body weight) or placebo for 18 months. The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
Measurements: Body composition and bone mineral density of the lumbar spine, femoral neck, and proximal radius were measured by dual energy x-ray absorptiometry at 6-month intervals. Markers of bone turnover were also measured during the first 12 months of the study.
Results: Growth hormone therapy increased bone mineral density in the lumbar spine by a mean (±SD) of 5.1% ± 4.1% and bone mineral density in the femoral neck by 2.4% ± 3.5%. In the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 ± 3.6 mg/L to 7.2 ± 4.6 mg/L) and urinary pyridinoline (39.0 ± 19.8 nmol/mmol of creatinine to 55.7 ± 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 ± 7.1 nmol/mmol of creatinine to 14.9 ± 9.4 nmol/mmol of creatinine). Percentage of body fat in the growth hormone group decreased (from 31.9% ± 6.5% to 28.3% ± 7.0%), and lean body mass increased (from 59.0 ± 8.5 kg to 61.5 ± 6.9 kg). These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
Conclusions: Growth hormone administered to men with adult-onset growth hormone deficiency at a dose adjusted according to serum IGF-1 levels increases bone density and stimulates bone turnover, decreases body fat and increases lean mass, and is associated with a low incidence of side effects.
Author and Article Information
From the Massachusetts General Hospital, Boston, Massachusetts; and the Maine Medical Center, Portland, Maine.
ARTICLE
Effects of Physiologic Growth Hormone Therapy on Bone Density and Body Composition in Patients with Adult-Onset Growth Hormone Deficiency
A Randomized, Placebo-Controlled Trial
![]()
Acknowledgments: The authors thank Drs. Andrew Perlman and Neil Gesundheit for their support of the study, Dr. Bernard Kliman for assistance with patient recruitment, Douglas Hayden for contributions to the statistical analysis, Dr. Leng Jiang for doing echocardiography, Jennifer Lord for study coordination and data entry, Jaime Paz for assistance with exercise testing, and the staff of the General Clinical Research Center at the Massachusetts General Hospital for their dedicated patient care.
Grant Support: In part by National Institutes of Health grants RR01066 and DK08783; Genentech, Inc.; and a grant from the American Philosophical Society.
Requests for Reprints: Anne Klibanski, MD, Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, BUL457B, Boston, MA 02114.
Current Author Addresses: Dr. Baum: 7777 Forest Lane, Suite C-218, Dallas, TX 75230.
Related articles in Annals:
This article has been cited by other articles:
![]() |
G S Conway, M Szarras-Czapnik, K Racz, A Keller, P Chanson, M Tauber, M Zacharin, and on behalf of the 1369 GHD to GHDA Transition Study Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency Eur. J. Endocrinol., June 1, 2009; 160(6): 899 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, M. A. Bredella, P. Tsai, N. Mendes, K. K. Miller, and A. Klibanski Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E385 - E392. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Beauregard, A. L. Utz, A. E. Schaub, L. Nachtigall, B. M. K. Biller, K. K. Miller, and A. Klibanski Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2063 - 2071. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, D. M. Bravata, I. Olkin, A. Friedlander, V. Liu, B. Roberts, E. Bendavid, O. Saynina, S. R. Salpeter, A. M. Garber, et al. Systematic Review: The Effects of Growth Hormone on Athletic Performance Ann Intern Med, May 20, 2008; 148(10): 747 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Falutz, S. Allas, K. Blot, D. Potvin, D. Kotler, M. Somero, D. Berger, S. Brown, G. Richmond, J. Fessel, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV N. Engl. J. Med., December 6, 2007; 357(23): 2359 - 2370. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Pilecka, C. Patrignani, R. Pescini, M.-L. Curchod, D. Perrin, Y. Xue, J. Yasenchak, A. Clark, M. C. Magnone, P. Zaratin, et al. Protein-tyrosine Phosphatase H1 Controls Growth Hormone Receptor Signaling and Systemic Growth J. Biol. Chem., November 30, 2007; 282(48): 35405 - 35415. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, D. M. Bravata, I. Olkin, S. Nayak, B. Roberts, A. M. Garber, and A. R. Hoffman Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly Ann Intern Med, January 16, 2007; 146(2): 104 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E494 - E503. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2154 - 2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Growth Hormone Treatment Improves Peripheral Muscle Oxygen Extraction-Utilization during Exercise in Patients with Human Immunodeficiency Virus-Associated Wasting: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5124 - 5131. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Hoffman, C. J. Strasburger, A. Zagar, W. F. Blum, A. Kehely, and M. L. Hartman Efficacy and Tolerability of an Individualized Dosing Regimen for Adult Growth Hormone Replacement Therapy in Comparison with Fixed Body Weight-Based Dosing J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3224 - 3233. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Hoffman, J. E. Kuntze, J. Baptista, H. B. A. Baum, G. P. Baumann, B. M. K. Biller, R. V. Clark, D. Cook, S. E. Inzucchi, D. Kleinberg, et al. Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2048 - 2056. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, and P. Chanson Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2192 - 2199. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Maison and P. Chanson Cardiac Effects of Growth Hormone in Adults With Growth Hormone Deficiency: A Meta-Analysis Circulation, November 25, 2003; 108(21): 2648 - 2652. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Underwood, K. M. Attie, and J. Baptista Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5273 - 5280. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Benbassat, V. Eshed, M. Kamjin, and Z. Laron Are Adult Patients with Laron Syndrome Osteopenic? A Comparison between Dual-Energy X-Ray Absorptiometry and Volumetric Bone Densities J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4586 - 4589. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. G. Maheshwari, R. Bouillon, J. Nijs, V. S. Oganov, A. V. Bakulin, and G. Baumann The Impact of Congenital, Severe, Untreated Growth Hormone (GH) Deficiency on Bone Size and Density in Young Adults: Insights from Genetic GH-Releasing Hormone Receptor Deficiency J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2614 - 2618. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Drake, P. V. Carroll, K. T. Maher, K. A. Metcalfe, C. Camacho-Hubner, N. J. Shaw, D. B. Dunger, T. D. Cheetham, M. O. Savage, and J. P. Monson The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1658 - 1663. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Murray and S. M. Shalet Adult Growth Hormone Replacement: Lessons Learned and Future Direction J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4427 - 4428. [Full Text] [PDF] |
||||
![]() |
W. L. Isley Growth Hormone Therapy for Adults: Not Ready for Prime Time? Ann Intern Med, August 6, 2002; 137(3): 190 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ezzat, S. Fear, R.-C. Gaillard, C. Gayle, H. Landy, S. Marcovitz, T. Mattioni, S. Nussey, A. Rees, and E. Svanberg Gender-Specific Responses of Lean Body Composition and Non-Gender-Specific Cardiac Function Improvement after GH Replacement in GH-Deficient Adults J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2725 - 2733. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kehely, P. C. Bates, P. Frewer, M. Birkett, W. F. Blum, P. Mamessier, S. Ezzat, K. K. Y. Ho, G. Lombardi, A. Luger, et al. Short-Term Safety and Efficacy of Human GH Replacement Therapy in 595 Adults with GH Deficiency: A Comparison of Two Dosage Algorithms J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1974 - 1979. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Christmas, K. G. O'Connor, S. M. Harman, J. D. Tobin, T. Munzer, M. F. Bellantoni, C. St. Clair, K. M. Pabst, J. D. Sorkin, and M. R. Blackman Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2002; 57(1): M12 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gotherstrom, J. Svensson, J. Koranyi, M. Alpsten, I. Bosaus, B.-A. Bengtsson, and G. Johannsson A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults: Sustained Effects on Body Composition, Bone Mass, and Metabolic Indices J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4657 - 4665. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524. [Abstract] [Full Text] |
||||
![]() |
G. Amato, G. Mazziotti, C. Di Somma, E. Lalli, G. De Felice, M. Conte, M. Rotondi, M. Pietrosante, G. Lombardi, A. Bellastella, et al. Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3720 - 3725. [Abstract] [Full Text] |
||||
![]() |
G. Sesmilo, B. M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial Ann Intern Med, July 18, 2000; 133(2): 111 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Osterziel, W. F. Blum, O. Strohm, and R. Dietz The Severity of Chronic Heart Failure due to Coronary Artery Disease Predicts the Endocrine Effects of Short- Term Growth Hormone Administration J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1533 - 1539. [Abstract] [Full Text] |
||||
![]() |
B.-A. Bengtsson and G. Johannsson The Treatment of Growth Hormone Deficiency in Adults J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 933 - 937. [Full Text] |
||||
![]() |
B. M. K. Biller, G. Sesmilo, H. B. A. Baum, D. Hayden, D. Schoenfeld, and A. Klibanski Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 970 - 976. [Abstract] [Full Text] |
||||
![]() |
D. M. Cook, W. H. Ludlam, and M. B. Cook Route of Estrogen Administration Helps to Determine Growth Hormone (GH) Replacement Dose in GH-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3956 - 3960. [Abstract] [Full Text] |
||||
![]() |
M. L. Vance and N. Mauras Growth Hormone Therapy in Adults and Children N. Engl. J. Med., October 14, 1999; 341(16): 1206 - 1216. [Full Text] [PDF] |
||||
![]() |
J. Gibney, J. D. Wallace, T. Spinks, L. Schnorr, A. Ranicar, R. C. Cuneo, S. Lockhart, K. G. Burnand, F. Salomon, P. H. Sonksen, et al. The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2596 - 2602. [Abstract] [Full Text] |
||||
![]() |
C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF] |
||||
![]() |
K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text] |
||||
![]() |
A. Colao, C. Di Somma, R. Pivonello, S. Loche, G. Aimaretti, G. Cerbone, A. Faggiano, G. Corneli, E. Ghigo, and G. Lombardi Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1919 - 1924. [Abstract] [Full Text] |
||||
![]() |
A. G. Johansson, B. E. Engström, S. Ljunghall, F. A. Karlsson, and P. Burman Gender Differences in the Effects of Long Term Growth Hormone (GH) Treatment on Bone in Adults with GH Deficiency J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2002 - 2007. [Abstract] [Full Text] |
||||
![]() |
Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): S2 - 40. [Full Text] [PDF] |
||||
![]() |
H. B. A. Baum, L. Katznelson, J. C. Sherman, B. M. K. Biller, D. L. Hayden, D. A. Schoenfeld, K. E. Cannistraro, and A. Klibanski Effects of Physiological Growth Hormone (GH) Therapy on Cognition and Quality of Life in Patients with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3184 - 3189. [Abstract] [Full Text] |
||||
![]() |
Y. J. H. Janssen, N. A. T. Hamdy, M. Frölich, and F. Roelfsema Skeletal Effects of Two Years of Treatment with Low Physiological Doses of Recombinant Human Growth Hormone (GH) in Patients with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2143 - 2148. [Abstract] [Full Text] |
||||
![]() |
C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text] |
||||
![]() |
P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text] |
||||
![]() |
I. M. Chapman, M. L. Hartman, S. S. Pezzoli, F. E. Harrell Jr., R. L. Hintz, K. G. M. M. Alberti, and M. O. Thorner Effect of Aging on the Sensitivity of Growth Hormone Secretion to Insulin-Like Growth Factor-I Negative Feedback J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2996 - 3004. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marcus M.D. and G. M. Reaven M.D. Growth Hormone--Ready for Prime Time? J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 725 - 726. [Full Text] [PDF] |
||||
![]() |
MIXED NEWS ON GROWTH HORMONE Journal Watch (General), December 13, 1996; 1996(1213): 1 - 1. [Full Text] |
||||